Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 7/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | GRM8 | O00222 | 2/20 | 1.00 |
| ▸ | GRM6 | O15303 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.50 |
| ▸ | GRM3 | Q14832 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659587 | 1.00 | GRM4 (1.00) | GRM4CYP1A2CYP2C19ALDH1A1TDP1 | |
| SCHEMBL3954836 | 1.00 | GRM4 (1.00) | GRM4CYP1A2CYP2C19ALDH1A1TDP1 | |
| SCHEMBL8476727 | 1.00 | GRM4 (1.00) | GRM4CYP1A2CYP2C19ALDH1A1TDP1 | |
| SCHEMBL12648585 | 1.00 | GRM4 (1.00) | GRM4CYP1A2CYP2C19ALDH1A1TDP1 | |
| SCHEMBL13319984 | 1.00 | GRM4 (1.00) | GRM4CYP1A2CYP2C19ALDH1A1TDP1 | |
| SCHEMBL3328641 | 1.00 | GRM4 (1.00) | GRM4CYP1A2CYP2C19ALDH1A1TDP1 | |
| SCHEMBL1064244 | 0.79 | CYP1A2 (1.00) | GRM4CYP1A2CYP2C19ALDH1A1TDP1 | |
| SCHEMBL1063416 | 0.79 | CYP1A2 (1.00) | GRM4CYP1A2CYP2C19ALDH1A1TDP1 | |
| SCHEMBL1263461 | 0.79 | CYP1A2 (1.00) | GRM4CYP1A2CYP2C19ALDH1A1TDP1 | |
| SCHEMBL15060220 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059886-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-20240091387-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | ALUME BIOSCIENCES INC (US) | 2024-03-21 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-11802138-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostic and therapeutic delivery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100015263-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2008138620-A2 | 1-AMINOCYCLOPENTANE-1,3,4-TRICARBOXYLIC ACIDS DERIVATIVES | FAUST PHARMACEUTICALS (FR) | 2008-11-20 | — | — | WO | disclosed |
| EP-1992610-A1 | New route of synthesis | Faust Pharmaceuticals (FR) | 2008-11-19 | — | — | EP | disclosed |
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | FAUST PHARMACEUTICALS (FR) | 2008-01-31 | — | — | US | disclosed |
| US-7129073-B2 | Regulation of neuronal function through metabotropic glutamate receptor signaling pathways | THE ROCKEFELLER UNIVERSITY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060223158-A1 | REGULATION OF NEURONAL FUNCTION THROUGH METABOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAYS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-05 | — | — | US | disclosed |
| WO-2005118533-A1 | TRANS PYRROLIDINYL DERIVATIVES AND THEIR PHARMACEUTICAL USE | FAUST PHARMACEUTICALS (FR) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118534-A1 | CIS PYRROLIDINYL DERIVATIVES AND THEIR USES | FAUST PHARMACEUTICALS (FR) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015263-A1 | CONTROLLED RELEASE AURIS SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, MYOC, S100B | GRM4 1414/4885CYP1A2 4738/4885CYP2C19 4793/4885 |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | GRM4 2836/4885CYP1A2 2820/4885CYP2C19 3504/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GRM4 2196/4885CYP1A2 3771/4885CYP2C19 4090/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | GRM4 649/4885CYP1A2 4845/4885CYP2C19 4805/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GRM4 2196/4885CYP1A2 3771/4885CYP2C19 4090/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | GRM4 3959/4885CYP1A2 3053/4885CYP2C19 3249/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | GRM4 2196/4885CYP1A2 3771/4885CYP2C19 4090/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | GRM4 2196/4885CYP1A2 3771/4885CYP2C19 4090/4885 |
| US-20080027127-A1 | Trans Pyrrolidinyl Derivates and Their Pharmaceutical Use | SUCNR1, GLRA1, CNR1 | GRM4 48/4885CYP1A2 1922/4885CYP2C19 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.